Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

Cytosorbents (CTSO) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $5.3 million.

  • Cytosorbents' Accumulated Depreciation & Amortization changed N/A to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year change of. This contributed to the annual value of $4.2 million for FY2024, which is 3919.49% up from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' Accumulated Depreciation & Amortization is $5.3 million.
  • In the past 5 years, Cytosorbents' Accumulated Depreciation & Amortization ranged from a high of $5.3 million in Q3 2025 and a low of $1.9 million during Q4 2022
  • Over the past 5 years, Cytosorbents' median Accumulated Depreciation & Amortization value was $4.6 million (recorded in 2025), while the average stood at $4.1 million.
  • As far as peak fluctuations go, Cytosorbents' Accumulated Depreciation & Amortization plummeted by 6015.87% in 2022, and later soared by 6006.97% in 2023.
  • Cytosorbents' Accumulated Depreciation & Amortization (Quarter) stood at $4.8 million in 2021, then tumbled by 60.16% to $1.9 million in 2022, then surged by 60.07% to $3.0 million in 2023, then surged by 39.19% to $4.2 million in 2024, then rose by 25.15% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q3 2025, $5.0 million for Q2 2025, and $4.6 million during Q1 2025.